M

MacroGenics
D

MGNX

3.09000
USD
0.09
(3.00%)
مغلق
حجم التداول
13,566
الربح لكل سهم
-3
العائد الربحي
-
P/E
-2
حجم السوق
193,939,054
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
    A
    ARRY
    -0.43000
    (-6.31%)
    6.38500 USD
    B
    BLUE
    -0.31000
    (-3.79%)
    7.86000 USD
    C
    CRSP
    2.740
    (6.61%)
    44.200 USD
    E
    EDIT
    0.15000
    (12.50%)
    1.35000 USD
    N
    NKTR
    0.02170
    (2.39%)
    0.93110 USD
    S
    SGMO
    0.03500
    (3.13%)
    1.15500 USD
    X
    XNCR
    0.250
    (1.22%)
    20.690 USD
    المزيد
الأخبار
المقالات

العنوان: MacroGenics

القطاع: Healthcare
الصناعة: Biotechnology
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. Its pipeline MGC018 (B7-H3), Lorigerlimab (PD-1 x CTLA-4), Tebotelimab (PD-1 x LAG-3), MGD024 (CD123 x CD3), IMGC936 (ADAM9), Enoblituzumab (anti-B7-H3), Retifanlimab (PD-1), and MGD014 (HIV x CD3).